Orally administered cholestyramine increases fecal bile acid excretion in healthy dogs
American Journal of Veterinary Research · 2025
DOI: 10.2460/ajvr.25.06.0230 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2025. Verfasst von M Katherine Tolbert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M Universit…. Hauptthemen laut MEDLINE: Cholestyramine Resin, Feces, Bile Acids and Salts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the effect of cholestyramine on the fecal dysbiosis index (DI) and the fecal excretion of conjugated and unconjugated bile acids (BAs) in dogs.
Methods
This was a prospective, pre-post experimental study. Individually housed research colony dogs were screened for inclusion. Included dogs were deemed healthy based on a lack of gastrointestinal signs and evaluation of annual blood work and fecal flotation. Cholestyramine was orally administered (53 to 75 mg/kg/d of active drug) to healthy dogs for 12 weeks. Dogs were maintained on the same maintenance diet for the entirety of the study. Feces were collected at 5 time points: 12 and 6 weeks prior to treatment, time 0, and 6 and 12 weeks during treatment. Repeated-measures 1-way ANOVAs were used to test differences over time for fecal conjugated and unconjugated BAs (time 0 and weeks 6 and 12 of treatment) and the fecal DI (all time points), including its individual bacterial taxa.
Results
12 dogs completed the study. No adverse events following cholestyramine treatment were observed. The DI was significantly lower following cholestyramine treatment compared to before treatment and was not outside of the reference range. Cholestyramine administration significantly increased total fecal BAs, which was largely driven by a significant increase in secondary unconjugated BAs.
Conclusions
Cholestyramine increased the total fecal BA excretion in colony dogs and had little to no clinical effect on the DI. Clinical Relevance These findings support the investigation of the use of cholestyramine in controlled clinical trials of dogs with suspected BA diarrhea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX.
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN.
- Office of Innovative Technologies, Research Computing Support, University of Tennessee, Knoxville, TN.
ORCID-Profile: M Katherine Tolbert, Rebecca E Bergee
Zitieren
APA
Tolbert, M. K., Michels, V., Blake, A., Kirk, C. A., Rollins, A. L., Bergee, R. E., Price, J. M., Suchodolski, J. S., & Murphy, M. (2025). Orally administered cholestyramine increases fecal bile acid excretion in healthy dogs. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.25.06.0230
Vancouver
Tolbert MK, Michels V, Blake A, Kirk CA, Rollins AL, Bergee RE, et al. Orally administered cholestyramine increases fecal bile acid excretion in healthy dogs. American Journal of Veterinary Research. 2025. doi:10.2460/ajvr.25.06.0230
BibTeX
@article{Tolbert2025,
author = {Tolbert, M Katherine and Michels, Vincent and Blake, Amanda and Kirk, Claudia A and Rollins, Angela L and Bergee, Rebecca E and Price, Josh M and Suchodolski, Jan S and Murphy, Maryanne},
title = {Orally administered cholestyramine increases fecal bile acid excretion in healthy dogs},
journal = {American Journal of Veterinary Research},
year = {2025},
doi = {10.2460/ajvr.25.06.0230}
}
EUVIMED